Hillary aide says biotech a winner

WASHINGTON - The Clinton administration provided a "significant victory" to the biotechnology industry by omitting price controls from the broad authority of the National Health Board that the White House would create under its health care plan, according to a key aide to Hillary Rodham Clinton.

The latest version of the plan calls for a "breakthrough drug committee" of the national board to review prices of new drugs, but gives the panel no authority to set or regulate prices. In addition, the plan would give the Department of Health and Human Services powers to exclude new drugs

Read the full 968 word article

How to gain access

Continue reading with a
two-week free trial.